Request Demo

Last update 08 May 2025

Rosoxacin

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid, Acrosoxacin, ROS

+ [5]

Target

Bacterial DNA gyrase x Bacterial top IV

Action

inhibitors

Mechanism

Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors)

Therapeutic Areas

Infectious DiseasesUrogenital Diseases

Active Indication

GonorrheaUrinary Tract Infections

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC17H14N2O3

InChIKeyXBPZXDSZHPDXQU-UHFFFAOYSA-N

CAS Registry40034-42-2

100 Clinical Results associated with Rosoxacin

100 Translational Medicine associated with Rosoxacin

100 Patents (Medical) associated with Rosoxacin

475

Literatures (Medical) associated with Rosoxacin

01 Apr 2025·Physiological Reports

Investigating the effects of rosmarinic acid on ovarian tissue, inflammatory markers, and sex hormones in polycystic ovary syndrome rats

Article

Author: Goharitaban, Sepide ; Amini, Fatemeh ; Vakili, Sina ; Hashempur, Mohammad Hashem ; Jafarinia, Morteza ; Samareh, Ali ; Savardashtaki, Amir ; Koohpeyma, Farhad ; Samare‐Najaf, Mohammad ; Namavar Jahromi, Bahia

AbstractPolycystic ovary syndrome (PCOS) causes the impairment of female fertility and elevates the risk of metabolic disorders. The current study aimed to evaluate the effects of rosmarinic acid (Ros) on the ovarian histo‐stereology, the level of reproductive hormones, and inflammation in a rat model of PCOS. Fifteen adult Sprague Dawley rats were randomly divided into three groups, including controls, PCOS, and PCOS+Ros (receiving 25 mg/kg of Ros for 39 days). After treatments, the ovarian histo‐stereology, the level of reproductive hormones, and the level of inflammatory markers were analyzed. PCOS led to increased ovarian weight and volume, cortical and medullary expansion, reduced ovarian follicles, and enhanced follicular atresia. It also caused hormonal imbalances, elevating LH, FSH, and testosterone while decreasing estradiol, progesterone, and AMH. Additionally, PCOS increased pro‐inflammatory markers (TNF‐α and IL‐6) and decreased anti‐inflammatory markers (IL‐4 and IL‐10). However, Ros administration in PCOS animals improved ovarian structure, increased follicle numbers, reduced atresia, balanced reproductive hormones, and restored inflammatory markers (p value <0.05). The present findings may suggest Ros as a novel strategy for the management of PCOS, although further studies are necessary.

01 Mar 2025·International Journal of Radiation Oncology*Biology*Physics

Changes in Employment and Practice Locations Among Radiation Oncologists: 2015-2023

Article

Author: Sindhu, Kunal K ; Lu, Sifan Grace ; Rowley, Jared P

PURPOSE/OBJECTIVESPrevious population-based studies of practice patterns among radiation oncologists (ROs) have focused on the overall supply of ROs rather than rates of job entry, turnover, and retirement, and have been limited to survey-based data. In this study, we aimed to examine trends in practice consolidation, characterize the frequency with which ROs have been entering and leaving the workforce, and quantify the proportion of ROs who have changed jobs.MATERIALS/METHODSWe utilized the Medicare Doctors and Clinicians National Downloadable File (NDF) to evaluate the employers and practice locations of ROs who practiced between 2015 and 2023. Employers were identified using tax-identification numbers and organization names. In addition, we determined the number of ROs who entered, stayed in, and left practice from year to year, and the number of ROs who changed employers and zip code. Solo and large practices were defined as employing one RO and ≥ 10 ROs, respectively.RESULTSThe number of large practices increased by 51% and the number of solo practices decreased by 27% between 2015 and 2023, resulting in a 13% decrease in the number of organizations that employed ROs. In addition, ROs retired (2.5% per year) and entered the workforce (4.1% per year) at steady rates, resulting in a 16% increase in the size of the RO workforce. Lastly, ROs changed jobs at a mean annual rate of 4.2%; female ROs, early-career physicians, solo-practitioners, and ROs from rural practices were most likely to undergo job changes.CONCLUSIONSROs are increasingly working in fewer and larger practices, indicative of a trend in practice size consolidation between 2015 and 2023. Rates of entry into and retirement from the workforce among ROs have been consistent, resulting in a steady and gradual increase in the number of practicing radiation oncologists. Lastly, ROs changed jobs at relatively consistent rates over the study period.

01 Feb 2025·Food Chemistry

Quantitative immunochromatographic assay for rapid detection of rosemary herb extract in ham sausage and dairy products

Article

Author: Guo, Lingling ; Kou, Shuai ; Xu, Chuanlai ; Sun, Maozhong ; Feng, Yongwei ; Li, Jinyan ; Kuang, Hua ; Yang, Ting

The important constituents of rosemary herb extract are carnosic acid (CarA), carnosol (Car) and rosmanol (Ros), which are burdensome to the human body when consumed in excessive amounts. Using a computer-assisted method, we prepared 3B10-antibody with both broad-spectrum and high affinity for CarA, Car and Ros with median inhibitory concentration of 0.41 ng/mL, 0.45 ng/mL, and 0.53 ng/mL, respectively. Subsequently, a quantitative lateral flow immunoassay (LFIA) was developed to identify CarA, Car and Ros in ham sausage and dairy within 30 min, and the respectively calculated limit of detection values of 0.044 μg/kg, 0.148 μg/kg and 0.169 μg/kg in sample, which could meet maximum additive limits. The quantitative results of LFIA method in positive samples were consistent with that of the instrumental method.These results also show that the high recognition performance and reliability of the LFIA strips validate the field test method.

100 Deals associated with Rosoxacin

External Link

KEGG	Wiki	ATC	Drug Bank
D02305	Rosoxacin	J01MB01	DB00817

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Gonorrhea	-	-	-
Urinary Tract Infections	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis